Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Abstract

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

Keywords

• psoriasis
• pustular psoriasis
• psoriatic arthritis
• imsidolimab
• spesolimab
• IL-36